A traditional Chinese medicine composition for treating mood and cognitive disorders caused by degenerative diseases

Abstract

The present application relates to the fields of medicine, health care products and food technology, and in particular to a traditional Chinese medicine composition for mood and cognitive impairment caused by degenerative diseases, which is made of the following raw materials by weight: 1-35 parts of radix puerariae, 1-35 parts of semen ziziphi spinosae, 1-35 parts of radix bupleuri, 1-35 parts of clematis, 1-35 parts of radix astragali, and 1-35 parts of herba eriodes. The present application has the effects of preventing and treating mood and cognitive impairment caused by various degenerative diseases, reducing anxiety-like response and depression level caused by degenerative diseases, preventing overexcitability of the nervous system, significantly improving learning and cognitive ability, and having stable effects without inhibiting normal nerve activity and hormone level.

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology for mood and cognitive disorders, specifically to a traditional Chinese medicine composition for mood and cognitive disorders caused by degenerative diseases. Background Technology

[0002] Degenerative diseases are pathological changes that cause atrophy and decline in the structure or function of tissues or organs. Some diseases can accelerate or directly lead to degenerative diseases, such as organic brain diseases, stroke, ovarian dysfunction, and gout. Degenerative diseases not only affect the structure and function of diseased tissues, but can also cause a variety of complications, including impacts on physical and mental health, directly or indirectly causing emotional and cognitive impairments in patients.

[0003] Neurodegenerative diseases are common and frequently occurring factors, often seen in cerebrovascular accidents such as Alzheimer's disease, cerebral infarction, and cerebral hemorrhage. They can directly damage the brain's neural tissue, leading to persistent degenerative changes in the central nervous system. For example, β-amyloid protein deposits in the brain to form plaques, or tau protein hyperphosphorylation during the recovery period after a cerebrovascular accident forms neurofibrillary tangles, causing gradual neuronal death. This is particularly severe in brain regions related to memory and cognition (such as the hippocampus), resulting in progressive memory loss, cognitive decline, and circadian rhythm disruption. If the lesions occur in areas closely related to emotion and cognition, such as the frontal lobe and temporal lobe, they can lead to corresponding functional impairments. For instance, infarction in the left cerebral hemisphere can cause aphasia and cognitive impairment. Patients often experience emotional problems such as depression and anxiety due to worry about the disease and changes in physical function. Long-term small vessel disease of the brain, such as lacunar infarction and white matter lesions, can also affect the blood supply and nerve conduction of the brain, gradually leading to a decline in cognitive function and vascular cognitive impairment. It may also be accompanied by emotional symptoms such as emotional instability and apathy.

[0004] Ovarian dysfunction primarily involves an imbalance in the hypothalamic-pituitary-ovarian axis (HPO axis), commonly seen in women during menopause when estrogen and progesterone secretion significantly decreases, feedback regulation weakens, and endocrine disorders occur. Peripherally, this manifests as an inability to maintain a normal hormonal cycle; centrally, it causes neurotransmitter and neuroregulatory disturbances, increased central excitability, and a tendency towards insomnia and anxiety, leading to mood regulation disorders such as depression, irritability, and poor concentration. Emotionally, it manifests as emotional instability, with frequent or persistent excessive mood swings, abnormally low or high moods, or excessive tension. Cognitively, it commonly manifests as memory loss, poor concentration, and difficulty in language expression and comprehension, severely impacting the patient's quality of life.

[0005] Modern basic medical research has found that the pathogenesis of degenerative diseases, due to different causes, mainly involves: 1. cellular senescence and functional decline; 2. oxidative stress and free radical damage; 3. chronic inflammation and immune imbalance; 4. protein misfolding and aggregation; 5. genetic and epigenetic factors; 6. environmental and mechanical factors; 7. imbalance between extracellular matrix degradation and tissue remodeling; and 8. impaired autophagy and metabolic waste clearance. Due to differing understandings of the macroscopic pathogenesis, clinical treatment plans vary, but none have addressed the induced emotional and cognitive impairments as primary symptoms, resulting in treatment outcomes that fail to meet clinical needs.

[0006] In Traditional Chinese Medicine (TCM), degenerative diseases are categorized differently depending on their location. For example, brain degenerative diseases can be classified as "atrophy syndrome," "stroke," or "phlegm and blood stasis syndrome," while ovarian insufficiency and menopausal syndrome fall under "visceral agitation" or "heart-kidney disharmony syndrome." These diseases involve various pathological factors such as wind, fire, phlegm, blood stasis, and deficiency. They can be caused by internal injury and overwork leading to brain marrow depletion, or by anger damaging the liver and causing liver yang hyperactivity; or by worry damaging the spleen, leading to internal phlegm and blood deficiency and empty meridians. It is evident that the etiologies and pathogenesis of various degenerative diseases are completely different in TCM theory, resulting in entirely different treatment principles and methods. On the other hand, emotional and cognitive impairments are considered secondary symptoms in TCM theory, falling under the category of the seven emotions, or serving as reference factors for basic diagnosis. They are generally not treated as primary symptoms, and the related pathogenesis and treatment theories are relatively brief compared to primary symptoms. Classic formulas for directly improving emotions and cognition are also rare. Therefore, the key problem this invention aims to solve is to combine formulas to treat these emotional and cognitive impairments caused by degenerative diseases. Summary of the Invention

[0007] The purpose of this invention is to provide a traditional Chinese medicine composition for treating emotional and cognitive impairments caused by degenerative diseases. This addresses the technical problem that existing technologies and prevention methods lack formulations primarily targeting emotional and cognitive impairments.

[0008] The objective of this invention is achieved as follows: a traditional Chinese medicine composition for treating emotional and cognitive impairment caused by degenerative diseases, characterized in that it comprises the following raw materials in parts by weight: 1-35 parts of kudzu root, 1-35 parts of jujube seed, 1-35 parts of bupleurum root, 1-35 parts of polygonum multiflorum stem, 1-35 parts of astragalus root, and 1-35 parts of scutellaria baicalensis flower.

[0009] The objective of this invention can also be achieved as follows: a traditional Chinese medicine composition for treating emotional and cognitive impairment caused by degenerative diseases, characterized in that: the raw materials are weighed according to the following parts by weight: 24 parts of kudzu root, 12 parts of jujube seed, 9 parts of bupleurum root, 30 parts of polygonum multiflorum stem, 18 parts of astragalus root, and 6 parts of scutellaria baicalensis flower; after mixing, they are pulverized into coarse powder, extracted with 10 times the amount of water under reflux for 4 hours, extracted twice, and concentrated under reduced pressure to 2g of crude drug / mL, thus obtaining the product.

[0010] A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, characterized in that: the raw materials are weighed according to the following parts by weight: 35g of kudzu root, 10g of jujube seed, 6g of bupleurum root, 35g of polygonum multiflorum stem, 16g of astragalus root, and 1g of scutellaria baicalensis flower; after mixing, they are pulverized into coarse powder, extracted with 10 times the amount of water under reflux for 4 hours, extracted twice, and concentrated under reduced pressure to 2g of crude drug / mL, which is the final product.

[0011] A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, characterized in that: the raw materials are weighed according to the following parts by weight: 8 parts of kudzu root, 30 parts of jujube seed, 16 parts of bupleurum root, 26 parts of polygonum multiflorum stem, 16 parts of astragalus root, and 10 parts of scutellaria baicalensis flower; after mixing, they are pulverized into coarse powder, extracted with 10 times the amount of water under reflux for 4 hours, extracted twice, and concentrated under reduced pressure to 2g of crude drug / mL, which is the final product.

[0012] The aforementioned traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases is used in the preparation of drugs for inhibiting memory loss, cognitive decline and anxiety-like behavior caused by neurodegenerative diseases, relieving nervous tension and depression, and inhibiting memory function decline.

[0013] The aforementioned traditional Chinese medicine composition for emotional and cognitive impairment caused by degenerative diseases is used in the preparation of drugs for improving mood regulation disorders caused by hormonal imbalances due to ovarian decline, reducing abnormal excitability of the hormone cycle-dependent center, relieving tension and anxiety, and preventing emotional instability and memory decline caused by hormonal imbalances.

[0014] The aforementioned traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases is used in the preparation of drugs for promoting hormone level stability, reducing abnormal excitation due to neuropsychiatric hormone dependence, improving mood disorders such as anxiety and depression, and promoting cognitive and memory recovery.

[0015] The beneficial effects of this invention are: it has the effect of preventing and treating emotional and cognitive impairments caused by various degenerative diseases, reducing anxiety-like reactions and depression levels caused by degenerative diseases; it prevents excessive nerve excitability, significantly improves learning and cognitive abilities, has stable effects, and has no inhibitory effect on normal nerve activity and hormone levels. Attached Figure Description

[0016] Figure 1 This is a schematic diagram of the experimental results of the composition of the present invention on the open field behavior of an ovarian decline model, showing that the composition can improve the anxiety-like behavior of the model.

[0017] Figure 2 This is a schematic diagram of the water maze test results of the composition of the present invention on an ovarian failure model. The reaction composition can improve the model's learning and memory abilities.

[0018] Figure 3This is a schematic diagram of the results of an elevated cross maze experiment on an ovarian failure model using the composition described in this invention. The reaction composition can alleviate the anxiety level of the model.

[0019] Figure 4 This is a schematic diagram showing the results of the composition of the present invention promoting sucrose preference and estrogen levels in an ovarian decline model. The composition can alleviate depressive-like behavior in the model and stabilize hormone levels.

[0020] Figure 5 This is a schematic diagram showing the results of the composition of the present invention promoting uterine development in an ovarian decline model.

[0021] Figure 6 This is a schematic diagram of the results of an open-field behavioral experiment on a mild stroke model using the combination described in this invention. The reaction composition can improve the anxiety-like behavior of the model.

[0022] Figure 7 This is a schematic diagram of the water maze test results of the combination of the present invention on a mild stroke model. The reaction composition can improve the model's learning and memory abilities.

[0023] Figure 8 This is a schematic diagram of the experimental results of the combination of the present invention promoting sucrose preference in a mild stroke model. The reaction composition can alleviate the depressive-like behavior of the model.

[0024] Figure 9 This is a schematic diagram illustrating the repair effect of the combination described in this invention on neurodegenerative lesions in brain tissue of a mild stroke model. Detailed Implementation

[0025] The technical solution of the present invention will be clearly and completely described below with reference to the accompanying drawings and embodiments. Obviously, the described embodiments are only a part of the technical solution of the present invention, and not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0026] A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, comprising the following ingredients by weight: 1-35 parts of kudzu root, 1-35 parts of jujube seed, 1-35 parts of bupleurum root, 1-35 parts of polygonum multiflorum stem, 1-35 parts of astragalus root, and 1-35 parts of scutellaria baicalensis flower.

[0027] This composition can significantly inhibit memory loss, cognitive decline, and anxiety-like behavior caused by neurodegenerative diseases, alleviate nervous tension and depression, and inhibit neurological function decline. It significantly improves mood regulation disorders caused by hormonal imbalances due to ovarian decline, reduces abnormal excitability of hormone cycle-dependent centers, alleviates tension and anxiety, and prevents emotional instability and memory decline caused by hormonal imbalances. This composition can promote stable hormone levels, reduce hormone-dependent abnormal excitability in the nervous and mental systems, improve mood disorders such as anxiety and depression, and promote cognitive and memory recovery.

[0028] Example 1: A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, comprising the following raw materials by weight: Pueraria lobata 24g, Ziziphus jujuba var. spinosa 12g, Bupleurum chinense 9g, Polygonum multiflorum 30g, Astragalus membranaceus 18g, and Erigeron breviscapus 6g. The medicinal materials in the specified proportions are pulverized into coarse powder, extracted with 10 times the amount of water under reflux for 4 hours, extracted twice, and concentrated under reduced pressure to 2g crude drug / mL to obtain the final product.

[0029] Example 2: A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, comprising the following raw materials by weight: 35g of kudzu root, 10g of jujube seed, 6g of bupleurum root, 35g of polygonum multiflorum stem, 16g of astragalus root, and 1g of scutellaria baicalensis flower. The medicinal materials in the specified proportions are pulverized into coarse powder, extracted with 10 times the amount of water under reflux for 4 hours, extracted twice, and concentrated under reduced pressure to 2g crude drug / mL to obtain the final product.

[0030] Example 3: A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, comprising the following raw materials by weight: 8 parts of kudzu root, 30 parts of jujube seed, 16 parts of bupleurum root, 26 parts of polygonum multiflorum stem, 16 parts of astragalus root, and 10 parts of scutellaria baicalensis flower. The medicinal materials in the specified proportions are pulverized into coarse powder, extracted with 10 times the amount of water under reflux for 4 hours, extracted twice, and concentrated under reduced pressure to 2g crude drug / mL to obtain the final product.

[0031] Experimental Example 1: In an experiment investigating the central nervous system excitability and cognitive impairment of a traditional Chinese medicine formula in an anti-ovarian decline (menopause) model, extracts prepared in Examples 1, 2, and 3 were used for drug administration studies. Sixty-six normal female BALB / c mice were randomly divided into 11 groups: a blank group, an ovariectomized menopausal model group, Example 1 group (low dose 2g / kg, once daily; medium dose 4g / kg, once daily; high dose 8g / kg, once daily); Example 2 group (low dose 2g / kg, once daily; medium dose 4g / kg, once daily; high dose 8g / kg, once daily); and Example 3 group (low dose 2g / kg, once daily; medium dose 4g / kg, once daily; high dose 8g / kg, once daily). An ovariectomized menopausal model was used, in which BALB / c mice were anesthetized, had their ovaries removed, were restrained for 4 hours daily for four weeks, and were subcutaneously injected with D-galactose to accelerate aging. After the model was completed, except for the model group which was given physiological saline, the other experimental groups were given the extract of the designed dose by gavage for two consecutive weeks.

[0032] Two weeks later, an open field experiment was conducted: In a quiet environment, the experimental mice were placed in an open field test chamber with dimensions of 50cm × 50cm × 40cm. A 30cm × 30cm square area was defined as the center, and the remaining areas were considered the perimeter. Mouse behavior tracking and timing devices were set up to observe all movement trajectories of each mouse within 5 minutes, recording the total distance the mouse moved within the field and the time spent in the central area. After each experiment, the equipment was wiped with 75% ethanol to avoid residual odor affecting the experiment.

[0033] Morris Water Maze Experiment: The Morris water maze experiment is a classic behavioral experimental method for evaluating learning and memory abilities. After each group of experimental animals completed drug administration, they underwent a 5-day orientation and navigation training program. Each day, mice were gently placed into the water facing the direction of a cue on the pool wall, starting from quadrants one through four. The time it took to find a platform each time (escape latency) and the total distance traveled to find the original platform location were recorded. Each mouse underwent training once per quadrant per day. If a mouse failed to find a platform within 60 seconds, the escape latency was recorded as 60 seconds. On day 6, a spatial exploration memory test was conducted. The platforms were removed, and mice were placed in the quadrant diagonally opposite the platforms. A camera system automatically recorded the mice's swimming trajectory over 300 seconds, recording the number of times the mice crossed the original platform location.

[0034] Elevated Plus Maze (EPM): The elevated plus maze test consists of open arms (OA) and closed arms (CA) arranged in a vertical cross shape. The open arms are 30 cm long and 5 cm wide, with no obstructions around them. The closed arms are 30 cm long and 5 cm wide, with a 25 cm high barrier around them. The entire maze is 80 cm above the ground. At the start of the experiment, mice are placed in the central area of ​​the maze (5 cm × 5 cm), with each mouse's head facing the same open arm. The total distance the mice travel, the time spent in the open and closed arms, and the number of times they enter the open and closed arms are recorded over 5 minutes to assess their anxiety level.

[0035] Sugar water preference test: This test assesses anhedonia in experimental animals to study depression-related states in animal models. The method involves simultaneously administering each test mouse a fixed amount (200g) of 1% sucrose solution and an equal weight of purified water. The consumption of both solutions within 2 hours is measured. The degree of preference for sugar water reflects the level of depression; the sugar water preference rate is calculated as: sugar water intake / total fluid intake x 100%.

[0036] Mice in each experimental group were sacrificed after the experiment, and uterine tissue was harvested to prepare pathological sections for HE staining to observe pathological changes. An enzyme-linked immunosorbent assay (ELISA) kit was used to determine the estradiol (E2) content in the plasma of rats in each group.

[0037] Experimental Example 2: In an experiment on the central nervous system excitability and cognitive impairment of a traditional Chinese medicine formula model of neurodegenerative disease (mild stroke), 66 normal male C57 mice were randomly divided into 11 groups: a blank control group, a stroke model group with ischemia-reperfusion using the suture occlusion method, Example 1 group (low dose 2g / kg, once daily; medium dose 4g / kg, once daily; high dose 8g / kg, once daily); Example 2 group (low dose 2g / kg, once daily; medium dose 4g / kg, once daily; high dose 8g / kg, once daily); and Example 3 group (low dose 2g / kg, once daily; medium dose 4g / kg, once daily; high dose 8g / kg, once daily). A neurodegenerative disease model after ischemia-reperfusion in mild stroke was established using the suture occlusion method. The suture was removed after 3 hours of ischemia, and the animals were allowed to recover for one week after model establishment to ensure no significant individual differences in dietary behavior and other conditions among the experimental groups. Except for the model group, which was given physiological saline, the other groups were given extracts of each embodiment of the designed dose by gavage and administered them continuously for two weeks.

[0038] Two weeks later, the open field test, Morris water maze test, and sucrose preference test were conducted in sequence. After the test, the mice in each experimental group were sacrificed, and brain tissue was cut out to make pathological sections for HE staining to observe pathological changes.

[0039] Analysis of the results of Experiment Example 1: (1) As Figure 1 As shown, the total distance traveled in the open field by the ovarian failure model (P<0.05) and the time to enter the central region (P<0.01) were significantly lower than those of the normal group, indicating an increased avoidance tendency towards dangerous environments in the model group and suggesting significant anxiety-like behavior. Compared with the model group, the total distance traveled by the three example groups increased, with the high-dose group showing the most significant increase (P<0.05). The time to enter the central region was significantly increased in the medium-dose and high-dose groups (P<0.05, P<0.01), suggesting that the anxiety levels of the three example groups in Experiment 1 were significantly improved compared with the ovarian failure model group, with the high-dose group showing the most significant improvement.

[0040] (2) For example Figure 2 As shown in Table 1, compared with the normal group, the ovarian infertility model group exhibited a significantly prolonged escape latency during water maze navigation training (P<0.05), with the difference becoming more significant as the learning time progressed. The total distance traveled also significantly increased (P<0.01), and the number of platform crossings in the memory test was significantly reduced (P<0.01). This indicates a significant decrease in spatial exploration memory ability in the ovarian infertility model group, suggesting a possible spatial memory impairment. Compared with the model group, the three implementation groups showed a reduced escape latency during water maze navigation training, with the reduction becoming more pronounced as the learning time progressed. The total distance traveled was also reduced compared to the model group, with the high-dose and medium-dose groups showing the most significant reduction (P<0.05). This suggests that the spatial memory level of the three implementation groups was improved to some extent compared with the ovarian infertility model group, with the medium- and high-dose groups showing more significant improvement.

[0041] (3) such as Figure 3 As shown, compared with the normal group, the time and number of times the ovarian failure model entered the open arm in the elevated cross maze were significantly reduced (P<0.01), indicating that the ovarian failure model group had a significantly increased avoidance of "highly open spaces," suggesting that the model exhibited significant anxiety-like behavior. Compared with the model group, the three example groups showed increased time and number of times they entered the open arm in the elevated cross maze, with the high-dose group showing a more significant increase (P<0.05), suggesting that the anxiety-like levels in the three dose groups of Experiment 1 were improved to some extent compared with the ovarian failure model group, with the high-dose group showing a more significant improvement.

[0042] (4) such as Figure 4As shown, the ovarian failure model showed a significant decrease in sucrose consumption compared to the normal group, indicating that the ovarian failure model showed a decreased interest in the previously preferred sucrose, consistent with depressive-like behavior. The sucrose consumption increased in all three example groups, with the high-dose group showing the most significant increase, suggesting that the depressive-like level in the three example groups in Experiment 1 was improved to some extent compared to the ovarian failure model group.

[0043] Estrogen levels were significantly lower in the ovarian failure model compared to the normal group. Estrogen levels increased in all three example groups, with the high-dose group showing the most significant increase. This suggests that administration of the drugs in the three examples in Experiment 1 can improve estrogen levels in the ovarian failure model.

[0044] (5) such as Figure 5 As shown in the HE staining of the uterus of mice in each experimental group, the overall morphology of the ovaries in the model group was smaller in volume, with a degenerated and flattened inner diameter outline, arrested development, abnormal follicle morphology, low developmental degree, and follicular atresia, reflecting the histological damage during ovarian dysfunction. In the three example groups of Experiment 1, partial destruction of the internal structure of the follicles was observed, with thinning of the granulosa cell layer and partial disordered arrangement (arrows), decreased density of ovarian stromal cells and density of cells around the follicles, and disordered distribution. These characteristics reflect partial ovarian dysfunction in the three dosage groups of Experiment 1, with histological damage significantly improved compared to the model group.

[0045] Analysis of the results of Experiment Example 2: (1) As Figure 6 As shown, compared with the normal group, the total distance traveled and the time to enter the central region in the open field of the mild stroke model were significantly reduced (P<0.01), and the behavioral trajectory showed a clear preference for the peripheral region, indicating increased excitability and a heightened avoidance tendency towards dangerous environments in the model group, suggesting significant anxiety-like behavior. Compared with the model group, the total distance traveled in the three example groups of Experiment 2 increased, with the high-dose group showing the most significant increase (P<0.05). The time to enter the central region was significantly increased in the medium-dose and high-dose groups (P<0.05, P<0.01), suggesting that the anxiety levels in the three dose groups of Experiment 2 were significantly improved compared with the mild stroke model group, with the high-dose group showing the most significant effect.

[0046] (2) For example Figure 7As shown in Table 2, compared with the normal group, the escape latency of the mild stroke model during water maze navigation training was significantly prolonged (P<0.01), and the difference became more significant with the progress of learning time. The total distance traveled was significantly increased (P<0.01), and the number of platform crossings in the memory test was significantly reduced (P<0.01), indicating that the mild stroke model group had a significantly reduced spatial exploration memory ability, suggesting that the model group may have spatial memory impairment. Compared with the model group, the escape latency of the three example groups in Experiment 2 was reduced during water maze navigation training, and the reduction was more significant with the progress of learning time. The total distance traveled was reduced compared with the model group, and the reduction was more significant in the medium and high dose groups (P<0.05), suggesting that the spatial memory level of the three dose groups in Experiment 2 was improved to some extent compared with the mild stroke model group, and the improvement effect was more significant in the medium and high dose groups.

[0047] (3) such as Figure 8 As shown, the sucrose consumption rate of the mild stroke model was significantly lower than that of the normal group, indicating that the mild stroke model showed a decreased interest in the previously preferred sucrose, which is consistent with depressive-like behavior characteristics. The sucrose consumption of the three example groups in Experiment 2 increased, with the high-dose group showing the most significant increase, suggesting that the depressive-like level of the three example groups in Experiment 2 was improved to some extent compared with the mild stroke model group.

[0048] (4) such as Figure 9 As shown, compared with the normal group, the mild stroke model group showed disordered tissue structure (arrows), cell damage, interstitial edema, and obvious neurodegenerative pathological changes, consistent with the histopathological characteristics of cerebral ischemia-reperfusion injury and cerebral infarction. In the three example groups of Experiment 2, the low-dose group may still have some residual pathological changes, and the signs of tissue repair are relatively weak. The medium-dose group showed a certain degree of structural improvement and a reduction in abnormal staining areas, suggesting that the drug intervention has a certain effect. If the tissue morphology of the high-dose group is closer to that of the normal group, it indicates that the high-dose drug may have a more significant pathological repair effect on cerebral ischemia injury and neurodegenerative lesions.

[0049] Table 1. Water maze swimming training time and number of cross-platform sessions

[0050] Table 2. Water maze swimming training time and number of cross-platform sessions

[0051] The significant advancements of this invention are reflected in the following: 1. This invention can significantly inhibit memory loss, cognitive decline and anxiety-like behavior caused by neurodegenerative diseases, relieve nervous tension and depression, and inhibit the decline of neurological function.

[0052] 2. This invention can significantly improve mood regulation disorders caused by hormonal imbalances due to ovarian decline, reduce abnormal excitability of the hormone cycle-dependent center, relieve tension and anxiety, and prevent emotional instability and memory decline caused by hormonal imbalances.

[0053] 3. This invention can significantly promote the stabilization of hormone levels, reduce abnormal excitation of the nervous and mental systems due to hormone dependence, improve mood disorders such as anxiety and depression, and promote the recovery of cognition and memory.

[0054] The above description is merely a specific embodiment of the present invention, and the scope of protection of the present invention is not limited thereto. Any variations or substitutions of technical solutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A traditional Chinese medicine composition for treating mood and cognitive impairment caused by degenerative diseases, characterized in that: It comprises the following ingredients by weight: 1-35g of kudzu root, 1-35g of jujube seed, 1-35g of bupleurum root, 1-35g of polygonum multiflorum stem, 1-35g of astragalus root, and 1-35g of scutellaria baicalensis flower.

2. The traditional Chinese medicine composition according to claim 1 for treating mood and cognitive impairment caused by degenerative diseases, characterized in that: Weigh the raw materials according to the following proportions by weight: 24g of kudzu root, 12g of jujube seed, 9g of bupleurum root, 30g of polygonum multiflorum stem, 18g of astragalus root, and 6g of scutellaria baicalensis flower; mix them and grind them into coarse powder, extract them by reflux with 10 times the amount of water for 4 hours, extract twice, and concentrate under reduced pressure to 2g of crude drug / mL to obtain the final product.

3. The traditional Chinese medicine composition according to claim 1 for treating mood and cognitive impairment caused by degenerative diseases, characterized in that: Weigh the raw materials according to the following proportions by weight: 35g of kudzu root, 10g of jujube seed, 6g of bupleurum root, 35g of polygonum multiflorum stem, 16g of astragalus root, and 1g of scutellaria baicalensis flower. Mix them and grind them into coarse powder. Extract them by reflux with 10 times the amount of water for 4 hours. Extract twice and concentrate under reduced pressure to 2g of crude drug / mL to obtain the final product.

4. The traditional Chinese medicine composition according to claim 1 for treating mood and cognitive impairment caused by degenerative diseases, characterized in that: Weigh the raw materials according to the following proportions by weight: 8 parts of kudzu root, 30 parts of jujube seed, 16 parts of bupleurum root, 26 parts of polygonum multiflorum stem, 16 parts of astragalus root, and 10 parts of scutellaria baicalensis flower. Mix them and grind them into coarse powder. Extract them by reflux with 10 times the amount of water for 4 hours. Extract twice and concentrate under reduced pressure to 2g of crude drug / mL to obtain the final product.

5. The traditional Chinese medicine composition according to any one of claims 1-4 for treating emotional and cognitive impairment caused by degenerative diseases, and its use in the preparation of a drug for inhibiting memory loss, cognitive decline and anxiety-like behavior caused by neurodegenerative diseases, relieving nervous tension and depression, and inhibiting memory function decline.

6. The traditional Chinese medicine composition according to any one of claims 1-4 for treating emotional and cognitive impairment caused by degenerative diseases, and its application in the preparation of a drug for improving mood regulation disorders caused by hormonal imbalances due to ovarian decline, reducing abnormal excitability of the hormone cycle-dependent center, relieving tension and anxiety, and preventing emotional instability and memory decline caused by hormonal imbalances.

7. The traditional Chinese medicine composition according to any one of claims 1-4 for treating emotional and cognitive disorders caused by degenerative diseases, and its application in the preparation of a medicine for promoting hormone level stability, reducing abnormal excitation due to neuropsychiatric hormone dependence, improving emotional disorders such as anxiety and depression, and promoting cognitive and memory recovery.

Images